Acting on the advice of its advisory committee, the FDA has approved new labeling for HESPAN® and certain other 6% hetastarch products that explicitly warn against their use in the three following circumstances: cardiac bypass pump prime, during cardiopulmonary bypass, and in the period immediately following pump discontinuation.

Revised HESPAN® labeling